DRIVe Funding Opportunity #11

Covid-19 At Home Diagnostics


sepsis cells

Program Overview


With “Covid-19 At Home Diagnostics,” DRIVe and BARDA's Detection, Diagnostics, & Devices Infrastructure (DDDI) division are seeking disruptive platform technologies to serve as reliable alternatives to traditional central laboratory testing. Covid-19 At Home diagnostics could enhance the capabilities of telemedicine by enabling data-driven diagnosis by healthcare providers without requiring sample shipping or travel to a sample collection site.


Image

Vision

Improved medical services and health outcomes – enhanced through sample collection and testing in the convenience of the patient’s home.

Strategy

To support the development and validation of new platform technologies for simple, rapid multiplexed analysis of biological specimens in the home setting – run by the patient, interpreted by the MD.




Program FAQ

Learn about our Covid-19 At Home Diagnostics program by checking out our frequently asked questions




Is this Funding Opportunity open to academics or do only companies qualify?

It is open to both academia and industries as long as the respondents meet all the requirements described in the EZ-BAA and the special instructions .


Any entity can submit proposal via the EZ-BAA portal as long as they are registered with www.SAM.gov.


Yes. Applicants from outside of the United States are eligible to apply for funding.


Yes. Abstract submissions should include a cost-share that is within our target range of minimum 30-50% minimum ,unless you satisfy the regulatory exception (included below for reference). Currently, none of the DRIVe partners under the DRIVe EZ-BAA have been awarded a contract that does not include a cost-share component below range, including all universities and non-profit organizations. Cost-share may be in-kind or cash contributions. It may also come from a third-party investor/sponsor, however, it is up to you to ensure you receive their contribution toward the proposed project. Many organizations offer to cover Overhead or Fringe Benefits. Some also offer pro-bono labor hours or sponsored equipment, materials, or subcontractor costs. A combination of all of the above could be acceptable. It would need to be indicated on a submission what is being cost-shared. To qualify for no cost-share under an EZ-BAA award, a respondent must show that there is "no probability that the respondent will receive present or future benefits from participation as described in Federal Acquisition Regulation (FAR) 16.303." Examples of present or future benefits include increased technical know-how, training for employees, acquisition of goods or services, development of a commercially viable product that can be sold in the commercial market, and use of background knowledge in future contracts.


Projects funded under this program have data sharing requirements with the U.S. government consistent with government regulation (FAR 52.227-14 Rights in Data). The program requires that you share all data (including raw data) generated under the project for government use consistent with the regulation.


While you can include links to figures or references, it is not mandated that reviewers view that outside information. At this time, the abstract format does not accept any figures, only text.








Submit your EZ BAA Abstract

For more information, please contact us at COVID19_homeDx@hhs.gov